ERTS Wealth Advisors LLC lifted its position in Edwards Lifesciences Corp (NYSE:EW) by 79.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,131 shares of the medical research company’s stock after buying an additional 500 shares during the period. ERTS Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $209,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 40.2% in the 1st quarter. Jennison Associates LLC now owns 5,763,824 shares of the medical research company’s stock valued at $1,102,792,000 after buying an additional 1,651,691 shares in the last quarter. BlackRock Inc. increased its holdings in Edwards Lifesciences by 4.7% during the 1st quarter. BlackRock Inc. now owns 17,211,498 shares of the medical research company’s stock worth $3,293,075,000 after purchasing an additional 780,079 shares in the last quarter. FMR LLC increased its holdings in Edwards Lifesciences by 7.9% during the 1st quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock worth $1,564,274,000 after purchasing an additional 598,976 shares in the last quarter. Bessemer Group Inc. increased its holdings in Edwards Lifesciences by 56,300.0% during the 2nd quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock worth $93,045,000 after purchasing an additional 502,759 shares in the last quarter. Finally, Thoroughbred Financial Services LLC increased its holdings in Edwards Lifesciences by 20,429.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 267,503 shares of the medical research company’s stock worth $26,750,000 after purchasing an additional 266,200 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company’s stock.

In related news, VP Huimin Wang sold 4,650 shares of the firm’s stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $186.17, for a total value of $865,690.50. Following the completion of the sale, the vice president now directly owns 36,898 shares in the company, valued at approximately $6,869,300.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $186.95, for a total transaction of $1,255,556.20. Following the completion of the sale, the vice president now owns 124,145 shares of the company’s stock, valued at $23,208,907.75. The disclosure for this sale can be found here. Insiders sold a total of 181,541 shares of company stock valued at $38,060,211 over the last quarter. 1.63% of the stock is currently owned by company insiders.

A number of research firms have issued reports on EW. BMO Capital Markets increased their target price on Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Canaccord Genuity increased their target price on Edwards Lifesciences from $215.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Raymond James increased their target price on Edwards Lifesciences from $200.00 to $232.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Jefferies Financial Group increased their target price on Edwards Lifesciences from $210.00 to $245.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Bank of America reiterated a “buy” rating and set a $225.00 target price (up previously from $215.00) on shares of Edwards Lifesciences in a report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $206.32.

Shares of Edwards Lifesciences stock traded down $1.68 during trading hours on Friday, reaching $218.77. 9,131 shares of the company’s stock were exchanged, compared to its average volume of 964,080. The company has a 50 day moving average of $217.31 and a two-hundred day moving average of $190.94. Edwards Lifesciences Corp has a fifty-two week low of $136.44 and a fifty-two week high of $228.19. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The stock has a market cap of $45.39 billion, a P/E ratio of 46.52, a P/E/G ratio of 2.75 and a beta of 0.84.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the business posted $1.24 EPS. The company’s quarterly revenue was up 15.2% on a year-over-year basis. As a group, analysts expect that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: What are no-load funds?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.